Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T65731
(Former ID: TTDI01311)
|
|||||
Target Name |
Nitric oxide elimination (NOE)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | NOX-700 | Drug Info | Phase 1 | Type-2 diabetes | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | NOX-700 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Inhibition of nitrosylation, nitration, lymphocyte proliferation, and gene expression in acute and delayed cardiac allograft rejection by an orally active dithiocarbamate. J Cardiovasc Pharmacol. 2004 Apr;43(4):522-30. | |||||
REF 2 | Clinical pipeline report, company report or official report of Medinox. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.